{"date":"2026-08-08","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6976-2026-08-08-1804-15br6jf","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2026-08-08","time":"18:04:40","subject":"代重要子公司Acepodia Biotech, Inc.公告研發中之ADC新藥ACE723向美國FDA提出人體臨床試驗審查申請","clause":"第8款","fact_date":"2026-08-08","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2026-08-08 18:04，「代重要子公司Acepodia Biotech, Inc.公告研發中之ADC新藥ACE723向美國FDA提出人體臨床試驗審」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6446-2026-08-08-1558-1o1ud6g","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2026-08-08","time":"15:58:00","subject":"本公司於115/8/8召開重大訊息說明記者會內容：本公司接獲國際商會國際仲裁院之第二階段「部分仲裁判斷」","clause":"第2款","fact_date":"2026-08-08","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2026-08-08 15:58，「本公司於115/8/8召開重大訊息說明記者會內容：本公司接獲國際商會國際仲裁院之第二階段「部分仲裁判斷」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}